1-Chlor-2-phenyl-1-cyclpropancarbonsaeure | 58486-07-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Chlor-2-phenyl-1-cyclpropancarbonsaeure
• 英文别名: trans-1-Chloro-2-phenylcyclopropane-1-carboxylic acid；1-chloro-2-phenylcyclopropane-1-carboxylic acid
• CAS: 58486-07-0
• 化学式: C₁₀H₉ClO₂
• 分子量: 196.633
• InChiKey: JNVVHSJFPOMXJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Chlor-2-phenyl-1-cyclpropancarbonsaeure 、 碘甲烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 2c-Phenyl-1-chlor-cyclopropan-1r-carbonsaeuremethylester 、 methyl cis-1-chloro-2-phenylcyclopropanecarboxylate
  参考文献：
  名称：

  SmI₂-Promoted Reformatsky-Type Reaction and Acylation of Alkyl 1-Chlorocyclopropanecarboxylates

  摘要：

  In the presence of HMPA in THF, highly stereoselective Sml(2)-promoted substitutions of alkyl 1-chlorocyclopropanecarboxylates 1 using various ketones, aldehydes (Reformatsky-type reaction), and acyl chlorides (acylation) proceeded to give trans-adducts (2 or 5) in good to high yield with excellent trans-stereoselectivity (trans-add/cis-add = > 99/1). The Reformatsky-type reaction of 1 with aldehydes and unsymmetrical ketones proceeded with moderate diastereoselectivity (re-face-adduct/si-face-adduct = 60/40-75/25).

  DOI：

  10.1021/ol8022038
• 作为产物：
  描述：

  1-chloro-2-phenylcyclopropane-1-carbaldehyde 在 Jones reagent 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 1-Chlor-2-phenyl-1-cyclpropancarbonsaeure
  参考文献：
  名称：

  SmI₂-Promoted Reformatsky-Type Reaction and Acylation of Alkyl 1-Chlorocyclopropanecarboxylates

  摘要：

  In the presence of HMPA in THF, highly stereoselective Sml(2)-promoted substitutions of alkyl 1-chlorocyclopropanecarboxylates 1 using various ketones, aldehydes (Reformatsky-type reaction), and acyl chlorides (acylation) proceeded to give trans-adducts (2 or 5) in good to high yield with excellent trans-stereoselectivity (trans-add/cis-add = > 99/1). The Reformatsky-type reaction of 1 with aldehydes and unsymmetrical ketones proceeded with moderate diastereoselectivity (re-face-adduct/si-face-adduct = 60/40-75/25).

  DOI：

  10.1021/ol8022038

文献信息

• Optimized synthesis of 2-substituted 1-halocyclopropane-1-carboxylic acids
  作者：A. A. Zagidullin、A. V. Zorin、V. V. Zorin

  DOI：10.1134/s1070363216100108

  日期：2016.10

  gem-dibromocyclopropanes with n-butyllithium in THF under argon at–78°С followed by purging the reaction mixture with dry CO2 was used to synthesize cis- and/or trans-1-halocyclopropane-1-carboxylic acids in 30–56% yields. The yields of the target products could be increased to 76–83% by the addition of an equimolar amount of LiCl to the reaction mixture. The highest salt effect was obtained with lithium

  在氩气下于–78°C下，使宝石-二氯和宝石-二溴环丙烷与正丁基锂在THF中反应，然后用干燥的CO 2吹扫反应混合物，以合成顺式和/或反式-1-卤代环丙烷-1 -羧酸的收率为30–56％。通过向反应混合物中添加等摩尔量的LiCl，可以将目标产物的收率提高到76-83％。用原位生成的氯化锂可获得最高的盐效应（88–96％）。
• SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
  申请人：Hartung Ingo

  公开号：US20090005373A1

  公开（公告）日：2009-01-01

  The invention relates to substituted sulfonamido-macrocycles according to the general formula (I): in which R 1 , R 2 , R 4 , R 5 , A, B, C, L, X, Y, Z, n, and m are as defined in the claims, and salts, N-oxides, or solvates thereof, to pharmaceutical compositions comprising said substituted sulfonamido-macrocycles, to methods of preparing said substituted sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及一般式（I）的取代磺酰胺基大环化合物：其中R1、R2、R4、R5、A、B、C、L、X、Y、Z、n和m如权利要求中所定义，并且其盐、N-氧化物或溶剂合物，以及包含所述取代磺酰胺基大环化合物的制药组合物，制备所述取代磺酰胺基大环化合物的方法以及将其用于制造治疗失调血管生长病或伴随失调血管生长的疾病的制药组合物的用途，其中该化合物有效干扰Tie2信号。
• Novel prostaglandin compounds, processes for the preparation thereof and pharmaceutical compositions containing them
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0002590A1

  公开（公告）日：1979-06-27

  The invention provides novel prostaglandin compounds and processes for the preparation thereof which are prostaglandins of the E, F, or A series having on the terminal methylene carbon of the alpha chain a substituent selected from the group consisting of wherein R is an alkyl group and R15 is C1-C4 alkyl, di-C1-C4- alkylamino and phenyl or phenyl substituted with one or more substituents selected from the group consisting of C1-C4 alkyl, OR, SR, F or C1 wherein R is as previously defined. Processes for the preparation of these compounds are described as well as pharmaceutical compositions containing them. The compounds have a potential utility in medicine as for example: hypotensive agents, anti-ulcer agents and bronchodilators.

  本发明提供了新型前列腺素化合物及其制备方法，这些化合物是 E、F 或 A 系列的前列腺素，其 α 链的末端亚甲基碳上有一个从以下组中选出的取代基：其中 R 是烷基，R15 是 C1-C4 烷基、二 C1-C4 烷基氨基和苯基或被一个或多个从以下组中选出的取代基取代的苯基，这些组包括 C1-C4 烷基、OR、SR、F 或 C1，其中 R 如前所定义。 本发明描述了这些化合物的制备方法以及含有这些化合物的药物组合物。 这些化合物在医药方面具有潜在的用途，例如：降血压剂、抗溃疡剂和支气管扩张剂。
• 16-Hydroxy-16-vinyl (or cyclopropyl)-prostan-1-ols and pharmaceutical compositions containing the same
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0013107A1

  公开（公告）日：1980-07-09

  There are disclosed novel 15-deoxy-16-hydroxy-16- substituted prostanoic acid analogs in which the C-1 carboxyl is replaced by a primary alcohol and carboxylic acid esters, carbonates and carbamates thereof, and which have utility as bronchodilators, as hypotensive agents, and as agents forthe control of excessive gastric secretion. The novel compounds are represented by the formula: wherein Q is a divalent cyclopentyl moiety selected from the group consisting of: wherein R/ is an alkyl (C3-C7) optionally substituted with one or more alkyl groups of one to three carbon atoms; R2 is selected from the group hydroxyl, alkoxyl, alkanoyloxy, a protecting group such as tetrahydropyran-2-yl-oxy, triloweralkylsilyloxy; or alkoxyalkoxy such as wherein R' is hydrogen or alkyl (C1-C4) and R" is alkyl (C1-C4); X is the divalent radical wherein R3 is selected from the group vinyl and cyclopropyl; Z is selected from the group -(CH2)4, cis and and W is selected from the group consisting of -(CH2)3 OH and wherein R4 is selected from the group alkyl (C,-C.); alkoxy (C1-C4); dialkylamino (C1-C4); phenyl and phenyl substituted with one or more substituents selected from the group consisting of hydrogen, hydroxyl, lower alkyl, lower alkoxy, loweralkylthia, fluoride or chloride, wherein lower alkyl is C1-C4; The formula above embraces the optical isomers, racemic or other mixtures of these isomers and the mirror images thereof

  公开了新型 15-脱氧-16-羟基-16-取代的前列酸类似物，其中 C-1 羧基被伯醇及其羧酸酯、碳酸酯和氨基甲酸酯取代，可用作支气管扩张剂、降压药和控制胃分泌过多的药物。这些新型化合物由式表示： 其中 Q 是二价环戊基，选自由以下组成的组： 其中 R/ 是任选被一个或多个一至三个碳原子的烷基取代的烷基（C3-C7）；R2 选自羟基、烷氧基、烷酰氧基、保护基团如四氢吡喃-2-基氧基、三烷基硅氧基；或烷氧基烷氧基，如 其中 R' 为氢或烷基（C1-C4），R" 为烷基（C1-C4）； X 为二价基 其中 R3 选自乙烯基和环丙基组； Z 选自-(CH2)4 组，顺式和逆式。 和 W 选自-( )3 OH 和-( )4-OH 所组成的组。 其中 R4 选自烷基（C,-C.）；烷氧基（C1-C4）；二烷基氨基（C1-C4）；苯基和被一个或多个取代基取代的苯基，取代基选自氢、羟基、低级烷基、低级烷氧基、低级烷硫基、氟化物或氯化物组成的组，其中低级烷基为 C1-C4； 上式包括这些异构体的光学异构体、外消旋体或其他混合物及其镜像。
• Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1873159A1

  公开（公告）日：2008-01-02

  The invention relates to substituted sulfonamido-macrocycles according to the general formula (I) : in which R1, R2, R4, R5, A, B, C, L, X, Y, Z, n, and m are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulfonamido-macrocycles, to methods of preparing said substituted sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及通式(I)的取代磺酰胺基大环： 其中 R1、R2、R4、R5、A、B、C、L、X、Y、Z、n 和 m 如权利要求中定义，及其盐，涉及包含所述取代的磺酰胺基-大环的药物组合物，涉及制备所述取代的磺酰胺基-大环的方法，以及使用其制造药物组合物，用于治疗血管生长失调疾病或伴随血管生长失调的疾病，其中所述化合物可有效干扰 Tie2 信号。